Cargando…

Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer

PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascula...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yun-Gyoo, Lee, Eunyoung, Kim, Inho, Lee, Keun-Wook, Kim, Tae Min, Lee, Se-Hoon, Kim, Dong-Wan, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614217/
https://www.ncbi.nlm.nih.gov/pubmed/25672586
http://dx.doi.org/10.4143/crt.2014.045
_version_ 1782396369908006912
author Lee, Yun-Gyoo
Lee, Eunyoung
Kim, Inho
Lee, Keun-Wook
Kim, Tae Min
Lee, Se-Hoon
Kim, Dong-Wan
Heo, Dae Seog
author_facet Lee, Yun-Gyoo
Lee, Eunyoung
Kim, Inho
Lee, Keun-Wook
Kim, Tae Min
Lee, Se-Hoon
Kim, Dong-Wan
Heo, Dae Seog
author_sort Lee, Yun-Gyoo
collection PubMed
description PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. MATERIALS AND METHODS: We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. RESULTS: Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. CONCLUSION: The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE.
format Online
Article
Text
id pubmed-4614217
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-46142172015-10-22 Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer Lee, Yun-Gyoo Lee, Eunyoung Kim, Inho Lee, Keun-Wook Kim, Tae Min Lee, Se-Hoon Kim, Dong-Wan Heo, Dae Seog Cancer Res Treat Original Article PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. MATERIALS AND METHODS: We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. RESULTS: Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. CONCLUSION: The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE. Korean Cancer Association 2015-10 2015-01-02 /pmc/articles/PMC4614217/ /pubmed/25672586 http://dx.doi.org/10.4143/crt.2014.045 Text en Copyright © 2015 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Yun-Gyoo
Lee, Eunyoung
Kim, Inho
Lee, Keun-Wook
Kim, Tae Min
Lee, Se-Hoon
Kim, Dong-Wan
Heo, Dae Seog
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
title Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
title_full Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
title_fullStr Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
title_full_unstemmed Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
title_short Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
title_sort cisplatin-based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614217/
https://www.ncbi.nlm.nih.gov/pubmed/25672586
http://dx.doi.org/10.4143/crt.2014.045
work_keys_str_mv AT leeyungyoo cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT leeeunyoung cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT kiminho cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT leekeunwook cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT kimtaemin cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT leesehoon cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT kimdongwan cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer
AT heodaeseog cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer